{
  "as_of": "2026-10-15",
  "fiscal_year_end": "December 31",
  "companies": [
    {
      "id": "hmg",
      "name": "Dr. Sulaiman Al Habib Medical Services Group",
      "ticker": "4013",
      "revenue": [
        7250.47,
        8310.74,
        9508.44,
        11200.43,
        13706.9
      ],
      "net_profit": [
        1376.62,
        1650.75,
        2046.01,
        2315.29,
        2401.47
      ],
      "sources": [
        "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en",
        "https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
      ],
      "driver_2025": "Higher volumes, occupancy, hospitals and pharmacies; newly opened hospitals' fixed costs compressed profit growth relative to revenue growth.",
      "caveats": [
        "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table.",
        "2024-25 expansion changes capacity, so growth is not same-store."
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "More patients and higher inpatient occupancy increased hospital and pharmacy sales; revenue growth and better margins lifted owner earnings.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=72057"
        },
        {
          "year": 2023,
          "explanation": "Higher patient volumes and inpatient occupancy expanded hospital/pharmacy revenue and improved profit margins.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=78283"
        },
        {
          "year": 2024,
          "explanation": "Hospital and pharmacy growth plus Al-Fayhaa and Shamal Riyadh openings drove sales; new hospitals were ramping up. A SAR44.84m unusual gain also supported reported earnings.",
          "source": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2024/1"
        },
        {
          "year": 2025,
          "explanation": "Higher volumes, occupancy, hospitals and pharmacies; newly opened hospitals' fixed costs compressed profit growth relative to revenue growth.",
          "source": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1"
        }
      ],
      "name_ar": "مجموعة سليمان الحبيب",
      "sector": "hospitals",
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_id": "S1"
    },
    {
      "id": "mouwasat",
      "name": "Mouwasat Medical Services",
      "ticker": "4002",
      "revenue": [
        2144.14,
        2334.11,
        2705.51,
        2879.37,
        3222.58
      ],
      "net_profit": [
        578.16,
        599.31,
        657.69,
        645.76,
        822.04
      ],
      "sources": [
        "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1",
        "https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en",
        "https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
      ],
      "driver_2025": "Patient visits and inpatient occupancy increased; lower ECL provisions, collections of older balances and lower borrowing costs helped profit. Yanbu pre-opening costs partly offset these gains.",
      "caveats": [
        "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m."
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "Outpatient visits, inpatient occupancy, specialist performance and efficiency improved. Dammam expansion and new Madinah hospital operating/nonoperating expenses restrained profit margins.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=72524"
        },
        {
          "year": 2023,
          "explanation": "Visits and occupancy rose, supported by projects opened in H2 2022, specialist resources and efficiency. Higher revenue, gross margin and other income supported earnings. Disclosure narrative confuses comprehensive income with profit: use the table and audited owner profit657.69m.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=78898"
        },
        {
          "year": 2024,
          "explanation": "Patient activity/new specialties lifted sales, but costs of increased long-term-care operations in Madinah reduced profit despite revenue growth.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=85612"
        },
        {
          "year": 2025,
          "explanation": "Patient visits and inpatient occupancy increased; lower ECL provisions, collections of older balances and lower borrowing costs helped profit. Yanbu pre-opening costs partly offset these gains.",
          "source": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1"
        }
      ],
      "name_ar": "المواساة",
      "sector": "hospitals",
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_id": "S2"
    },
    {
      "id": "dallah",
      "name": "Dallah Healthcare",
      "ticker": "4004",
      "revenue": [
        2105.18,
        2487.98,
        2942.9,
        3205.73,
        4066.89
      ],
      "net_profit": [
        258.6,
        274.46,
        360.12,
        471.2,
        538.27
      ],
      "sources": [
        "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false",
        "https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true",
        "https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021",
        "https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
      ],
      "driver_2025": "Al Khobar and Al Ahsa acquisitions consolidated from 23 March 2025 contributed SAR 572m, 66.4% of revenue increase. Existing medical facilities added SAR 289m. Higher associates' contribution and smaller Al Khobar losses helped.",
      "caveats": [
        "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings.",
        "2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables.",
        "Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series.",
        "2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments."
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "Higher patients and occupancy grew revenue; associate losses narrowed. SAR21m supplier provision, historical zakat assessments and higher Murabaha costs restrained profit. Use table owner profit274.46m: narrative contains conflicting group/owner figures.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=72468"
        },
        {
          "year": 2023,
          "explanation": "Higher hospital visits, occupancy and capacity lifted revenue/gross profit; associate losses fell by SAR21m. Prior-year SAR18.5m zakat provision and favorable revised2023 assessments supported the comparison.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=78716"
        },
        {
          "year": 2024,
          "explanation": "Capacity and patient growth and efficiency increased revenue/gross margin; associates contributed SAR43m profit versus SAR2m loss.",
          "source": "https://www.argaam.com/en/financial-reports/company-report/1181/2024/1?isNoHeaderFooter=true"
        },
        {
          "year": 2025,
          "explanation": "Al Khobar and Al Ahsa acquisitions consolidated from 23 March 2025 contributed SAR 572m, 66.4% of revenue increase. Existing medical facilities added SAR 289m. Higher associates' contribution and smaller Al Khobar losses helped.",
          "source": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false"
        }
      ],
      "name_ar": "دله الصحية",
      "sector": "hospitals",
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_id": "S3"
    },
    {
      "id": "sgh",
      "name": "Middle East Healthcare (Saudi German Health)",
      "ticker": "4009",
      "revenue": [
        1872.62,
        2151.74,
        2653.17,
        2882.82,
        3102.63
      ],
      "net_profit": [
        17.2,
        75.18,
        17.04,
        null,
        null
      ],
      "sources": [
        "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1",
        "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72",
        "https://www.argaam.com/en/financial-reports/company-report/4475/2025/1",
        "https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf",
        "https://hail.saudigermanhealth.com/en/node/7826",
        "https://saudigermanhealth.com/en/node/7923",
        "https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf",
        "https://saudigermanhealth.com/en/node/7923",
        "https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
      ],
      "driver_2025": "Higher patient volumes, bed expansion, one-off Hajj hospital operating contract, lower financing costs and SAR114m land-sale gain.",
      "caveats": [
        "2023 NET PROFIT RESTATED: 17.04m, versus originally reported 180.18m. Official 2024 annual report confirms ~17m and 1555% growth to 282m in 2024. Stale issuer IR overview still shows 180.18m; do not use it for 2023.",
        "2024 contains SAR64.82m unusual gains and 2025 about SAR114m land-sale gain; Argaam recurring EPS falls in 2025 despite reported profit growth.",
        "2024/2025 annual profits 282.00/301.88m are historical annual disclosures SUPERSEDED by H1 2026 IAS8 corrections. Note24 supplies full-year balance-sheet restatements and interim income bridges, but no explicit latest full-year owner-attributable profits. Do not rank or calculate latest comparable profit CAGR from these figures. H1 2026 auditor issued a qualified review conclusion; annual restated audited profits remain unverified.",
        "12 March 2026 correction added audit emphasis-of-matter regarding Note26 related-party transactions/balances under common control, without qualifying opinion.",
        "H1 2026 Note24: retained earnings at 1Jan2025 reduced SAR238.719162m; at 31Dec2025 reduced397.591429m, both with matching PPE reductions. These cumulative balance-sheet corrections are not annual profit figures. Further review and adjustments may be required."
      ],
      "superseded_profit_years": [
        2024,
        2025
      ],
      "exclude_from_latest_comparable_profit_rankings": true,
      "net_profit_latest_comparable": [
        17.2,
        75.18,
        17.04,
        null,
        null
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "Patient growth, revised key-customer prices, accreditation/case mix and new-facility efficiency lifted earnings; three newly opened facilities contributed54m negative results.",
          "source": "https://jeddah.saudigermanhealth.com/en/node/7145"
        },
        {
          "year": 2023,
          "explanation": "Revenue expanded with patients/capacity, but the later17.04m owner-profit comparative includes historical2015–20 zakat assessments (2024 annual note38). Do not repeat the original180.18m growth narrative as the latest annual outcome.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=85527"
        },
        {
          "year": 2024,
          "explanation": "Historical annual explanation: more patients, beds/clinics utilization and MoH/insurance/cash activity,19.6m land gain, and nonrecurrence of prior-year zakat assessments. Profit282m is now superseded by2026 corrections.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=85527"
        },
        {
          "year": 2025,
          "explanation": "Higher patient volumes, bed expansion, one-off Hajj hospital operating contract, lower financing costs and SAR114m land-sale gain.",
          "source": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1"
        }
      ],
      "name_ar": "السعودي الألماني",
      "sector": "hospitals",
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_id": "S4",
      "superseded_profit": {
        "2024": 282,
        "2025": 301.88
      }
    },
    {
      "id": "care",
      "name": "National Medical Care",
      "ticker": "4005",
      "revenue": [
        845.38,
        917.93,
        1081.78,
        1293.69,
        1600.36
      ],
      "net_profit": [
        136.36,
        170.07,
        240.93,
        294.7,
        318.47
      ],
      "sources": [
        "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf",
        "https://www.argaam.com/en/financial-reports/company-report/2298/2025/1",
        "https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf",
        "https://ca.investing.com/equities/national-medical-care-co-financial-summary"
      ],
      "driver_2025": "Patient volumes grew 33%; referrals grew, Al Salam contributed a full year, ReLib expanded. Improved cost absorption and lower ECL provisions supported profit.",
      "caveats": [
        "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative.",
        "2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%.",
        "Full-year acquisition contribution makes growth non-organic."
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "Financial bridge: revenue grew faster than cost of revenue, gross profit rose and ECL fell from9.0m to5.0m, partly offset by higher administrative/marketing expenses. This is a statement-derived explanation, not a verified management causal narrative.",
          "source": "https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf"
        },
        {
          "year": 2023,
          "explanation": "More GOSI/MoH admissions and surgeries and higher MoH billing following HIMSS accreditation lifted revenue; better mix/cost absorption, ECL reversals, interest income and zakat reversals supported profit. National Guard long-term-care contract ended.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=78408"
        },
        {
          "year": 2024,
          "explanation": "Patient count rose14%, GOSI/MoH/insurance activity expanded and Chronic Care contributed a full year; Al Salam joined inQ4. Better cost absorption and roughly72m legal/zakat reversals helped reported profit. Use revised294.70m comparative.",
          "source": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf"
        },
        {
          "year": 2025,
          "explanation": "Patient volumes grew 33%; referrals grew, Al Salam contributed a full year, ReLib expanded. Improved cost absorption and lower ECL provisions supported profit.",
          "source": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf"
        }
      ],
      "name_ar": "رعاية",
      "sector": "hospitals",
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_id": "S5"
    },
    {
      "id": "alhammadi",
      "name": "Al Hammadi Holding",
      "ticker": "4007",
      "revenue": [
        951.89,
        1122.4,
        1176.76,
        1153.88,
        1234.53
      ],
      "net_profit": [
        90.09,
        257.34,
        303.33,
        338.8,
        241.86
      ],
      "sources": [
        "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en",
        "https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
      ],
      "driver_2025": "Revenue rose 7% but profit fell with loss of 2024 land-sale gain, higher operating expenses and ECL provision, goodwill impairment and lower finance income.",
      "caveats": [
        "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit.",
        "2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m.",
        "2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference."
      ],
      "annual_drivers": [
        {
          "year": 2022,
          "explanation": "Higher inpatient/outpatient volumes lifted medical and pharmaceutical revenue. ECL fell from154.47m to54.34m; prior-year8.78m Olaya discontinued loss did not recur.",
          "source": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/"
        },
        {
          "year": 2023,
          "explanation": "Revised insurer price lists and in-house pharmacy sales lifted revenue; better collections reduced ECL65% to19m, lifting profit faster than sales.",
          "source": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?locale=en&anId=78783"
        },
        {
          "year": 2024,
          "explanation": "Revenue declined on lower pharmaceutical and MoH contribution following tighter isolation rules. Reported profit increased with55.27m land gain and lower selling/marketing expenses.",
          "source": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2024-12-31/"
        },
        {
          "year": 2025,
          "explanation": "Revenue rose 7% but profit fell with loss of 2024 land-sale gain, higher operating expenses and ECL provision, goodwill impairment and lower finance income.",
          "source": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/"
        }
      ],
      "name_ar": "الحمادي",
      "sector": "hospitals",
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_id": "S6"
    },
    {
      "id": "almoosa",
      "name": "Almoosa Health",
      "name_ar": "الموسى الصحية",
      "ticker": "4018",
      "revenue": [
        701.542238,
        816.039139,
        978.974695,
        1202.336437,
        1416.284548
      ],
      "net_profit": [
        62.419568,
        51.015616,
        null,
        49.353369,
        236.541397
      ],
      "net_profit_original_2023": 98.146131,
      "sources": [
        "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf",
        "https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf",
        "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf",
        "https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
      ],
      "basis_notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "driver_2025": "Patient volume/service expansion and lower finance costs after IPO debt repayments; derivative fair-value items materially change net profit. Do not equate379% reported profit growth with operational growth.",
      "driver_2024": "Higher volumes and rehabilitation ramp-up drove revenue; depreciation and finance costs rose as assets entered service; derivative correction separately lowered comparative profit.",
      "sector": "hospitals",
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_id": "S7"
    },
    {
      "id": "fakeeh",
      "name": "Fakeeh Care",
      "name_ar": "فقيه الطبية",
      "ticker": "4017",
      "revenue": [
        1964.684,
        2012.391,
        2326.69,
        2790.9,
        3090.2
      ],
      "net_profit": [
        334.282,
        326.317,
        279.595,
        287.6,
        290.2
      ],
      "sources": [
        "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf",
        "https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf",
        "https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
      ],
      "basis_notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "driver_2023": "Riyadh startup losses181.6m at group level; owned60.56% explains owners-profit versus group-profit difference. Revenue rose15.6%, but depreciation/finance and ramp-up pressured earnings.",
      "driver_2025": "Revenue growth10.7%; new Riyadh/Madinah facilities scaling, but costs and receivable impairment increased. Operating profit fell14.2%; finance costs fell48.9%, supporting nearly flat owners' profit. Group profit fell5.9%.",
      "sector": "hospitals",
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_id": "S8"
    },
    {
      "id": "smc",
      "name": "SMC Healthcare",
      "name_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "revenue": [
        1053.12367,
        1208.651638,
        1367.929,
        1437.8,
        1538.5
      ],
      "net_profit": [
        55.967019,
        102.960668,
        168.7,
        185.2,
        266.2
      ],
      "sources": [
        "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf",
        "https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf",
        "https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf",
        "https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf",
        "https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
      ],
      "basis_notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "driver_2025": "Clinics/service-mix shift and efficiency; net profit includes60.6m one-off land gain.2025 reported netprofit266.2 less gain60.6 equals205.6m illustrative pre-tax-adjustment subtraction, not issuer adjusted earnings, so do not label audited recurring netprofit.",
      "driver_2024": "Growing medical and pharmacy activity; higher finance costs and expected credit losses offset operating progress.",
      "sector": "hospitals",
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_id": "S9"
    },
    {
      "id": "nahdi",
      "name": "Nahdi",
      "name_ar": "النهدي",
      "sector": "pharmacies",
      "ticker": "4164",
      "revenue": [
        8066.22,
        8616.2,
        8713.7,
        9446.42,
        10213.24
      ],
      "net_profit": [
        812.53,
        887.8,
        892.6,
        820.72,
        830.74
      ],
      "sources": [
        "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1",
        "https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en",
        "https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1",
        "https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
      ],
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_id": "S10"
    },
    {
      "id": "dawaa",
      "name": "Al-Dawaa",
      "name_ar": "الدواء",
      "sector": "pharmacies",
      "ticker": "4163",
      "revenue": [
        5034.382,
        5372.243,
        5741.364,
        6454.354,
        6736.196
      ],
      "net_profit": [
        239.145,
        305.449,
        302.992,
        351.408,
        321.756
      ],
      "sources": [
        "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf",
        "https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
      ],
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_id": "S11"
    },
    {
      "id": "2070",
      "ticker": "2070",
      "name": "SPIMACO",
      "name_ar": "سبيماكو الدوائية",
      "sector": "pharma",
      "revenue": [
        1459.78,
        1421.81,
        1655.44,
        1682,
        1706.71
      ],
      "net_profit": [
        26.45,
        -165.14,
        -50.73,
        24.54,
        184.36
      ],
      "sources": [
        "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71",
        "https://www.argaam.com/en/financial-reports/company-report/75/2024/1",
        "https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true",
        "https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf",
        "https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
      ],
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_id": "S12"
    },
    {
      "id": "4015",
      "ticker": "4015",
      "name": "Jamjoom Pharma",
      "name_ar": "جمجوم فارما",
      "sector": "pharma",
      "revenue": [
        735.68,
        916.67,
        1100.82,
        1318.48,
        1500.63
      ],
      "net_profit": [
        170.7,
        171.31,
        292.4,
        356.52,
        463.8
      ],
      "sources": [
        "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71",
        "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1",
        "https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
      ],
      "notes": "\"\"",
      "source_id": "S13"
    },
    {
      "id": "4016",
      "ticker": "4016",
      "name": "Avalon Pharma",
      "name_ar": "أفالون فارما",
      "sector": "pharma",
      "revenue": [
        287.222,
        302.662,
        338.44,
        394,
        460.49
      ],
      "net_profit": [
        66.283,
        59.452,
        65.83,
        79.85,
        97.01
      ],
      "sources": [
        "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf",
        "https://www.argaam.com/en/financial-reports/company-report/16437/2024/1",
        "https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1",
        "https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
      ],
      "notes": "\"\"",
      "source_id": "S14"
    },
    {
      "id": "smile",
      "ticker": "9626",
      "name": "Smile Care (Basma Adeem Medical)",
      "name_ar": "سمايل كير",
      "sector": "clinics",
      "revenue": [
        null,
        21.922123,
        26.524465,
        33.918786,
        45.4569
      ],
      "net_profit": [
        null,
        3.783343,
        4.869379,
        6.300855,
        7.304596
      ],
      "sources": [
        "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
      ],
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_id": "S15"
    },
    {
      "id": "mudaawat",
      "ticker": "9594",
      "name": "Al Mudaawat Specialized Medical",
      "name_ar": "المداواة",
      "sector": "clinics",
      "revenue": [
        40.837386,
        58.56579,
        74.308118,
        75.487734,
        121.820505
      ],
      "net_profit": [
        -2.2,
        10.313266,
        18.59267,
        6.073209,
        18.975232
      ],
      "sources": [
        "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf",
        "https://www.argaam.com/ar/article/articledetail/id/1717264",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar",
        "https://www.argaam.com/ar/article/articledetail/id/1700773"
      ],
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_id": "S16"
    },
    {
      "id": "future",
      "ticker": "9544",
      "name": "Future Care Trading",
      "name_ar": "الرعاية المستقبلية",
      "sector": "clinics",
      "revenue": [
        72.028,
        34.125,
        50.98,
        53.644,
        76.062
      ],
      "net_profit": [
        36.701,
        5.127,
        13.663,
        9.853,
        15.753
      ],
      "sources": [
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en",
        "https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
      ],
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_id": "S17"
    },
    {
      "id": "equipment",
      "ticker": "4014",
      "name": "Scientific and Medical Equipment House",
      "name_ar": "دار المعدات",
      "sector": "suppliers",
      "revenue": [
        699.453,
        713.821,
        776.666162,
        877.232651,
        876.707
      ],
      "net_profit": [
        77.524,
        17.567,
        40.058545,
        26.168089,
        28.439
      ],
      "sources": [
        "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf",
        "https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf",
        "https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
      ],
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_id": "S18"
    }
  ],
  "rows": [
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Dr. Sulaiman Al Habib Medical Services Group",
      "company_ar": "مجموعة سليمان الحبيب",
      "ticker": "4013",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 7250.47,
      "net_profit_attributable_to_owners": 1376.62,
      "net_margin_percent": 18.986631211493872,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en | https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
    },
    {
      "net_profit_growth_percent": 19.913265824991665,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Dr. Sulaiman Al Habib Medical Services Group",
      "company_ar": "مجموعة سليمان الحبيب",
      "ticker": "4013",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 8310.74,
      "net_profit_attributable_to_owners": 1650.75,
      "net_margin_percent": 19.862852164789178,
      "revenue_growth_percent": 14.623465789114354,
      "net_profit_original_superseded": null,
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en | https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
    },
    {
      "net_profit_growth_percent": 23.94426775708012,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Dr. Sulaiman Al Habib Medical Services Group",
      "company_ar": "مجموعة سليمان الحبيب",
      "ticker": "4013",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 9508.44,
      "net_profit_attributable_to_owners": 2046.01,
      "net_margin_percent": 21.51783047482026,
      "revenue_growth_percent": 14.411472383927304,
      "net_profit_original_superseded": null,
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en | https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
    },
    {
      "net_profit_growth_percent": 13.161225995962877,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Dr. Sulaiman Al Habib Medical Services Group",
      "company_ar": "مجموعة سليمان الحبيب",
      "ticker": "4013",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 11200.43,
      "net_profit_attributable_to_owners": 2315.29,
      "net_margin_percent": 20.671438507271596,
      "revenue_growth_percent": 17.794611944756443,
      "net_profit_original_superseded": null,
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en | https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
    },
    {
      "net_profit_growth_percent": 3.722211904340278,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Dr. Sulaiman Al Habib Medical Services Group",
      "company_ar": "مجموعة سليمان الحبيب",
      "ticker": "4013",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 13706.9,
      "net_profit_attributable_to_owners": 2401.47,
      "net_margin_percent": 17.520154082980106,
      "revenue_growth_percent": 22.3783372602659,
      "net_profit_original_superseded": null,
      "notes": "2024 Argaam unusual gains SAR 44.84m; 2025 no unusual item identified in Argaam annual table. 2024-25 expansion changes capacity, so growth is not same-store.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4433/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93107&locale=en | https://www.hmg.com/ir/annualreports/2024/financial-statement.html"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Mouwasat Medical Services",
      "company_ar": "المواساة",
      "ticker": "4002",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2144.14,
      "net_profit_attributable_to_owners": 578.16,
      "net_margin_percent": 26.964657158581062,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1 | https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en | https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
    },
    {
      "net_profit_growth_percent": 3.658156911581556,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Mouwasat Medical Services",
      "company_ar": "المواساة",
      "ticker": "4002",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2334.11,
      "net_profit_attributable_to_owners": 599.31,
      "net_margin_percent": 25.67616778986423,
      "revenue_growth_percent": 8.859962502448537,
      "net_profit_original_superseded": null,
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1 | https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en | https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
    },
    {
      "net_profit_growth_percent": 9.741202382740166,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Mouwasat Medical Services",
      "company_ar": "المواساة",
      "ticker": "4002",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2705.51,
      "net_profit_attributable_to_owners": 657.69,
      "net_margin_percent": 24.309279950914984,
      "revenue_growth_percent": 15.911846485384151,
      "net_profit_original_superseded": null,
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1 | https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en | https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
    },
    {
      "net_profit_growth_percent": -1.8139244933023213,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Mouwasat Medical Services",
      "company_ar": "المواساة",
      "ticker": "4002",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2879.37,
      "net_profit_attributable_to_owners": 645.76,
      "net_margin_percent": 22.42712815650646,
      "revenue_growth_percent": 6.426145163019159,
      "net_profit_original_superseded": null,
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1 | https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en | https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
    },
    {
      "net_profit_growth_percent": 27.298067393458858,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Mouwasat Medical Services",
      "company_ar": "المواساة",
      "ticker": "4002",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 3222.58,
      "net_profit_attributable_to_owners": 822.04,
      "net_margin_percent": 25.508753855606376,
      "revenue_growth_percent": 11.9196213060496,
      "net_profit_original_superseded": null,
      "notes": "Use owners' profit: 2023 total consolidated profit was 688.39m versus 657.69m attributable; 2022 632.69m versus 599.31m.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/1524/2025/1 | https://mouwasat.eurolandir.com/media/u4gd2wmc/mouwasat_annualreport_2023_en.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93624&locale=en | https://ca.marketscreener.com/quote/stock/MOUWASAT-MEDICAL-SERVICES-10016654/valuation/"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Dallah Healthcare",
      "company_ar": "دله الصحية",
      "ticker": "4004",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2105.18,
      "net_profit_attributable_to_owners": 258.6,
      "net_margin_percent": 12.28398521741609,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_urls": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false | https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true | https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021 | https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
    },
    {
      "net_profit_growth_percent": 6.133023975251328,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Dallah Healthcare",
      "company_ar": "دله الصحية",
      "ticker": "4004",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2487.98,
      "net_profit_attributable_to_owners": 274.46,
      "net_margin_percent": 11.031439159478772,
      "revenue_growth_percent": 18.183718256871153,
      "net_profit_original_superseded": null,
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_urls": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false | https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true | https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021 | https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
    },
    {
      "net_profit_growth_percent": 31.21037673977993,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Dallah Healthcare",
      "company_ar": "دله الصحية",
      "ticker": "4004",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2942.9,
      "net_profit_attributable_to_owners": 360.12,
      "net_margin_percent": 12.236909171225662,
      "revenue_growth_percent": 18.28471289962139,
      "net_profit_original_superseded": null,
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_urls": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false | https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true | https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021 | https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
    },
    {
      "net_profit_growth_percent": 30.84527379762301,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Dallah Healthcare",
      "company_ar": "دله الصحية",
      "ticker": "4004",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 3205.73,
      "net_profit_attributable_to_owners": 471.2,
      "net_margin_percent": 14.698680175810189,
      "revenue_growth_percent": 8.93098644194501,
      "net_profit_original_superseded": null,
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_urls": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false | https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true | https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021 | https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
    },
    {
      "net_profit_growth_percent": 14.233870967741936,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Dallah Healthcare",
      "company_ar": "دله الصحية",
      "ticker": "4004",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 4066.89,
      "net_profit_attributable_to_owners": 538.27,
      "net_margin_percent": 13.235420677716881,
      "revenue_growth_percent": 26.8631481752986,
      "net_profit_original_superseded": null,
      "notes": "2025 includes non-recurring SAR 51m in-kind land contribution gain and SAR 29.5m Murabaha remeasurement gain; do not equate reported growth with organic earnings. 2021 headline at time 258.3m differs from subsequently displayed 258.60m; latter corroborated in 2022 comparative and financial tables. Some annual report summaries use total group net profit (275m in 2021;295m 2022), rather than owner-attributable profit in this series. 2025 Q4 includes SAR 12m historical white-land fees and SAR17m obsolete inventory/supply-penalty adjustments.",
      "source_urls": "https://www.argaam.com/en/company/company-business-segments/marketid/3/companyid/1181/1/4?isfullpage=false | https://www.argaam.com/en/financial-reports/company-report/1181/2025/1?isNoHeaderFooter=true | https://www.argaam.com/en/company/financial-result/market/3/fptype/4/2021 | https://uk.investing.com/equities/dallah-healthcare-hold-co-financial-summary | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93455&locale=en"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Middle East Healthcare (Saudi German Health)",
      "company_ar": "السعودي الألماني",
      "ticker": "4009",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1872.62,
      "net_profit_attributable_to_owners": 17.2,
      "net_margin_percent": 0.9184992150035778,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72 | https://www.argaam.com/en/financial-reports/company-report/4475/2025/1 | https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf | https://hail.saudigermanhealth.com/en/node/7826 | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
    },
    {
      "net_profit_growth_percent": 337.09302325581405,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Middle East Healthcare (Saudi German Health)",
      "company_ar": "السعودي الألماني",
      "ticker": "4009",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2151.74,
      "net_profit_attributable_to_owners": 75.18,
      "net_margin_percent": 3.493916551256193,
      "revenue_growth_percent": 14.905319819290618,
      "net_profit_original_superseded": null,
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72 | https://www.argaam.com/en/financial-reports/company-report/4475/2025/1 | https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf | https://hail.saudigermanhealth.com/en/node/7826 | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
    },
    {
      "net_profit_growth_percent": -77.33439744612929,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Middle East Healthcare (Saudi German Health)",
      "company_ar": "السعودي الألماني",
      "ticker": "4009",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2653.17,
      "net_profit_attributable_to_owners": 17.04,
      "net_margin_percent": 0.6422505908027001,
      "revenue_growth_percent": 23.30346603214144,
      "net_profit_original_superseded": null,
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72 | https://www.argaam.com/en/financial-reports/company-report/4475/2025/1 | https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf | https://hail.saudigermanhealth.com/en/node/7826 | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2024-12-31",
      "completeness": "revenue_only",
      "company": "Middle East Healthcare (Saudi German Health)",
      "company_ar": "السعودي الألماني",
      "ticker": "4009",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2882.82,
      "net_profit_attributable_to_owners": null,
      "net_margin_percent": null,
      "revenue_growth_percent": 8.655683578511741,
      "net_profit_original_superseded": 282,
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72 | https://www.argaam.com/en/financial-reports/company-report/4475/2025/1 | https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf | https://hail.saudigermanhealth.com/en/node/7826 | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2025-12-31",
      "completeness": "revenue_only",
      "company": "Middle East Healthcare (Saudi German Health)",
      "company_ar": "السعودي الألماني",
      "ticker": "4009",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 3102.63,
      "net_profit_attributable_to_owners": null,
      "net_margin_percent": null,
      "revenue_growth_percent": 7.624825691510395,
      "net_profit_original_superseded": 301.88,
      "notes": "2024/25 historical annual profits superseded by2026 restatement process, qualified interim review; explicit latest annual owners profit reconciliation not verified. Excluded from derived margins/rankings.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/4475/2024/72 | https://www.argaam.com/en/financial-reports/company-report/4475/2025/1 | https://saudigermanhealth.com/investor-relations-reports/files/board-reports/annual-report-en-2024.pdf | https://hail.saudigermanhealth.com/en/node/7826 | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf | https://saudigermanhealth.com/en/node/7923 | https://saudigermanhealth.com/investor-relations-reports/files/result-center/financial-statements/quarter/2026/report-en-31-june-2026.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "National Medical Care",
      "company_ar": "رعاية",
      "ticker": "4005",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 845.38,
      "net_profit_attributable_to_owners": 136.36,
      "net_margin_percent": 16.130024367739953,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_urls": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf | https://www.argaam.com/en/financial-reports/company-report/2298/2025/1 | https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf | https://ca.investing.com/equities/national-medical-care-co-financial-summary"
    },
    {
      "net_profit_growth_percent": 24.721325902024027,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "National Medical Care",
      "company_ar": "رعاية",
      "ticker": "4005",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 917.93,
      "net_profit_attributable_to_owners": 170.07,
      "net_margin_percent": 18.527556567494255,
      "revenue_growth_percent": 8.58193948283612,
      "net_profit_original_superseded": null,
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_urls": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf | https://www.argaam.com/en/financial-reports/company-report/2298/2025/1 | https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf | https://ca.investing.com/equities/national-medical-care-co-financial-summary"
    },
    {
      "net_profit_growth_percent": 41.665196683718484,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "National Medical Care",
      "company_ar": "رعاية",
      "ticker": "4005",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1081.78,
      "net_profit_attributable_to_owners": 240.93,
      "net_margin_percent": 22.271626393536582,
      "revenue_growth_percent": 17.8499449849117,
      "net_profit_original_superseded": null,
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_urls": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf | https://www.argaam.com/en/financial-reports/company-report/2298/2025/1 | https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf | https://ca.investing.com/equities/national-medical-care-co-financial-summary"
    },
    {
      "net_profit_growth_percent": 22.317685634831697,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "National Medical Care",
      "company_ar": "رعاية",
      "ticker": "4005",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1293.69,
      "net_profit_attributable_to_owners": 294.7,
      "net_margin_percent": 22.779800415864695,
      "revenue_growth_percent": 19.5890107045795,
      "net_profit_original_superseded": null,
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_urls": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf | https://www.argaam.com/en/financial-reports/company-report/2298/2025/1 | https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf | https://ca.investing.com/equities/national-medical-care-co-financial-summary"
    },
    {
      "net_profit_growth_percent": 8.0658296572786,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "National Medical Care",
      "company_ar": "رعاية",
      "ticker": "4005",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1600.36,
      "net_profit_attributable_to_owners": 318.47,
      "net_margin_percent": 19.899897523057312,
      "revenue_growth_percent": 23.705060717791724,
      "net_profit_original_superseded": null,
      "notes": "2024 comparative 294.70m in 2025 annual report; older sources show 298.2m. Use latest annual comparative. 2024 contained ~SAR72m one-off legal and zakat reversals. Excluding them 2025 profit rose ~43%, versus reported 8.1%. Full-year acquisition contribution makes growth non-organic.",
      "source_urls": "https://ir.care.med.sa/media/2ldnui20/care-medical-annual-report-2025-en.pdf | https://www.argaam.com/en/financial-reports/company-report/2298/2025/1 | https://www.care.med.sa/upload/cvs/Sustainability-Report-2022-En.pdf | https://ca.investing.com/equities/national-medical-care-co-financial-summary"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Al Hammadi Holding",
      "company_ar": "الحمادي",
      "ticker": "4007",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 951.89,
      "net_profit_attributable_to_owners": 90.09,
      "net_margin_percent": 9.464328861528118,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_urls": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/ | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en | https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
    },
    {
      "net_profit_growth_percent": 185.6476856476856,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Al Hammadi Holding",
      "company_ar": "الحمادي",
      "ticker": "4007",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1122.4,
      "net_profit_attributable_to_owners": 257.34,
      "net_margin_percent": 22.92765502494654,
      "revenue_growth_percent": 17.912784040172713,
      "net_profit_original_superseded": null,
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_urls": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/ | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en | https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
    },
    {
      "net_profit_growth_percent": 17.871298671018888,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Al Hammadi Holding",
      "company_ar": "الحمادي",
      "ticker": "4007",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1176.76,
      "net_profit_attributable_to_owners": 303.33,
      "net_margin_percent": 25.776708929603316,
      "revenue_growth_percent": 4.843193157519599,
      "net_profit_original_superseded": null,
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_urls": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/ | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en | https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
    },
    {
      "net_profit_growth_percent": 11.693535093792251,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Al Hammadi Holding",
      "company_ar": "الحمادي",
      "ticker": "4007",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1153.88,
      "net_profit_attributable_to_owners": 338.8,
      "net_margin_percent": 29.36180538704198,
      "revenue_growth_percent": -1.944321696862561,
      "net_profit_original_superseded": null,
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_urls": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/ | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en | https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
    },
    {
      "net_profit_growth_percent": -28.612750885478157,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Al Hammadi Holding",
      "company_ar": "الحمادي",
      "ticker": "4007",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1234.53,
      "net_profit_attributable_to_owners": 241.86,
      "net_margin_percent": 19.59126145172657,
      "revenue_growth_percent": 6.989461642458483,
      "net_profit_original_superseded": null,
      "notes": "2021 net profit 90.09m includes discontinued Olaya loss SAR8.78m; continuing-operations figure ~98.87m must not replace total net profit. 2024 nonrecurring vacant-land gain SAR55.27m; 2025 goodwill impairment SAR4.3m and ECL21.11m vs9.07m. 2022 original revenue announcement1122.39m versus later comparative1122.40m, a rounding difference.",
      "source_urls": "https://alhammadi.com/al-hammadi-holding-announces-its-annual-financial-results-for-the-period-ending-on-2022-12-31/ | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78783&cs=4007&locale=en | https://www.argaam.com/sa-en/financial-reports/company-report/3438/2025/1 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93658&cs=4007&locale=en"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Almoosa Health",
      "company_ar": "الموسى الصحية",
      "ticker": "4018",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 701.542238,
      "net_profit_attributable_to_owners": 62.419568,
      "net_margin_percent": 8.897478244210863,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_urls": "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf | https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf | https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
    },
    {
      "net_profit_growth_percent": -18.26983486973187,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Almoosa Health",
      "company_ar": "الموسى الصحية",
      "ticker": "4018",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 816.039139,
      "net_profit_attributable_to_owners": 51.015616,
      "net_margin_percent": 6.25161387020188,
      "revenue_growth_percent": 16.320742329986416,
      "net_profit_original_superseded": null,
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_urls": "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf | https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf | https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2023-12-31",
      "completeness": "revenue_only",
      "company": "Almoosa Health",
      "company_ar": "الموسى الصحية",
      "ticker": "4018",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 978.974695,
      "net_profit_attributable_to_owners": null,
      "net_margin_percent": null,
      "revenue_growth_percent": 19.966634958179384,
      "net_profit_original_superseded": 98.146131,
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_urls": "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf | https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf | https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Almoosa Health",
      "company_ar": "الموسى الصحية",
      "ticker": "4018",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1202.336437,
      "net_profit_attributable_to_owners": 49.353369,
      "net_margin_percent": 4.104788600031424,
      "revenue_growth_percent": 22.815885143997505,
      "net_profit_original_superseded": null,
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_urls": "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf | https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf | https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
    },
    {
      "net_profit_growth_percent": 379.2811550514413,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Almoosa Health",
      "company_ar": "الموسى الصحية",
      "ticker": "4018",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1416.284548,
      "net_profit_attributable_to_owners": 236.541397,
      "net_margin_percent": 16.701544709644036,
      "revenue_growth_percent": 17.794363076430674,
      "net_profit_original_superseded": null,
      "notes": "2025 Arabic annual report printed pp162-163 shows five-year figures. FY2024 and2025 latest audited are49.353369 and236.541397. Note35 printedpp218-221 corrects derivative accounting under IFRS9/IAS8;2024 originally94.423973 reduced45.070604. Opening2024 retained earnings reduced46.399295. The five-year board table still carries2023 original98.146131, while Argaam carries51.75; no explicit primary 2023 income reconciliation verified. Thus2023 profit quarantined from comparable trend, preserved as original disclosure only. 2021–22 original basis also not proven fully retrospectively restated. No netprofit CAGR computed.",
      "source_urls": "https://ir.almoosahealthgroup.org/wp-content/uploads/2026/04/Almoosa_Health_ARA_AR2025_Book_804_1604.pdf | https://www.saudiexchange.sa/Resources/fsPdf/6846_0_2026-04-01_04-52-11_En.pdf | https://ir.almoosahealthgroup.org/wp-content/uploads/2026/03/Earnings-presentation_FY-2025_v12-3.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/16511/2025/1"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Fakeeh Care",
      "company_ar": "فقيه الطبية",
      "ticker": "4017",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1964.684,
      "net_profit_attributable_to_owners": 334.282,
      "net_margin_percent": 17.014542796704202,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_urls": "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf | https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
    },
    {
      "net_profit_growth_percent": -2.3827187823454388,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Fakeeh Care",
      "company_ar": "فقيه الطبية",
      "ticker": "4017",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2012.391,
      "net_profit_attributable_to_owners": 326.317,
      "net_margin_percent": 16.215387566332783,
      "revenue_growth_percent": 2.4282276437330497,
      "net_profit_original_superseded": null,
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_urls": "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf | https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
    },
    {
      "net_profit_growth_percent": -14.317979142980597,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Fakeeh Care",
      "company_ar": "فقيه الطبية",
      "ticker": "4017",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2326.69,
      "net_profit_attributable_to_owners": 279.595,
      "net_margin_percent": 12.016856564475715,
      "revenue_growth_percent": 15.618187519224636,
      "net_profit_original_superseded": null,
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_urls": "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf | https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
    },
    {
      "net_profit_growth_percent": 2.863069797385509,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Fakeeh Care",
      "company_ar": "فقيه الطبية",
      "ticker": "4017",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 2790.9,
      "net_profit_attributable_to_owners": 287.6,
      "net_margin_percent": 10.304919559998567,
      "revenue_growth_percent": 19.951519110839854,
      "net_profit_original_superseded": null,
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_urls": "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf | https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
    },
    {
      "net_profit_growth_percent": 0.9040333796940025,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Fakeeh Care",
      "company_ar": "فقيه الطبية",
      "ticker": "4017",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 3090.2,
      "net_profit_attributable_to_owners": 290.2,
      "net_margin_percent": 9.390977930231054,
      "revenue_growth_percent": 10.724139166577086,
      "net_profit_original_superseded": null,
      "notes": "Owners' profit; not total group profit.2025 owners290.2 vs group248.1 because NCI absorbs42.1 losses.2022 prospectus updated2023 comparison326.317 vs older326.316 rounding.2024–25 primary earnings release rounded0.1m, retained as such. IPO2024. Riyadh hospital acquiredOct29,2022; full consolidation2023 affects comparison.",
      "source_urls": "https://assets.website-files.com/62f3e6d489b8b9be90c5b53e/6629695208a6f6121cee0cbe_Fakeeh%20Prospectus%20-%20Eng_V13%2BWrapper.pdf | https://www.saudiexchange.sa/Resources/fsPdf/20894_5826_2026-03-03_22-14-10_en.pdf | https://www.argaam.com/sa-en/financial-reports/company-report/4286/2025/1"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "SMC Healthcare",
      "company_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "sector": "hospitals",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1053.12367,
      "net_profit_attributable_to_owners": 55.967019,
      "net_margin_percent": 5.314382402970774,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf | https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf | https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf | https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf | https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
    },
    {
      "net_profit_growth_percent": 83.966682234764,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "SMC Healthcare",
      "company_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "sector": "hospitals",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1208.651638,
      "net_profit_attributable_to_owners": 102.960668,
      "net_margin_percent": 8.518638850345065,
      "revenue_growth_percent": 14.768253001093413,
      "net_profit_original_superseded": null,
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf | https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf | https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf | https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf | https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
    },
    {
      "net_profit_growth_percent": 63.84897580501323,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "SMC Healthcare",
      "company_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "sector": "hospitals",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1367.929,
      "net_profit_attributable_to_owners": 168.7,
      "net_margin_percent": 12.332511409583391,
      "revenue_growth_percent": 13.17810335023928,
      "net_profit_original_superseded": null,
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf | https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf | https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf | https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf | https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
    },
    {
      "net_profit_growth_percent": 9.7806757557795,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "SMC Healthcare",
      "company_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "sector": "hospitals",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1437.8,
      "net_profit_attributable_to_owners": 185.2,
      "net_margin_percent": 12.880790095979968,
      "revenue_growth_percent": 5.107794337279192,
      "net_profit_original_superseded": null,
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf | https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf | https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf | https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf | https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
    },
    {
      "net_profit_growth_percent": 43.7365010799136,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "SMC Healthcare",
      "company_ar": "إس إم سي للرعاية الصحية",
      "ticker": "4019",
      "sector": "hospitals",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1538.5,
      "net_profit_attributable_to_owners": 266.2,
      "net_margin_percent": 17.302567435814105,
      "revenue_growth_percent": 7.0037557379329485,
      "net_profit_original_superseded": null,
      "notes": "2021–22 special-purpose consolidated audited prospectus statements.2024 revenue latest2025 comparative1437.8 rather than IPO1439.6; latest2024/25 rounded0.1m. IPO2025.2025 includes60.6m nonrecurring land-sale contribution gain, not all operational earnings.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-06-11_09-27-01_1.pdf | https://ipo.smc.com.sa/media/5gzjt2oc/smc-offering-circular.pdf | https://www.saudiexchange.sa/Resources/fsPdf/27433_7686_2026-03-31_23-20-49_en.pdf | https://ir.smc.com.sa/media/3odnibjy/smc_ar2025_v5_arabic_31022026.pdf | https://www.argaam.com/ar/financial-reports/company-report/17867/2024/1?preview=true"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Nahdi",
      "company_ar": "النهدي",
      "ticker": "4164",
      "sector": "pharmacies",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 8066.22,
      "net_profit_attributable_to_owners": 812.53,
      "net_margin_percent": 10.073243725065767,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_urls": "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1 | https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en | https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1 | https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
    },
    {
      "net_profit_growth_percent": 9.263657957244664,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Nahdi",
      "company_ar": "النهدي",
      "ticker": "4164",
      "sector": "pharmacies",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 8616.2,
      "net_profit_attributable_to_owners": 887.8,
      "net_margin_percent": 10.303846243123417,
      "revenue_growth_percent": 6.818311427161672,
      "net_profit_original_superseded": null,
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_urls": "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1 | https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en | https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1 | https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
    },
    {
      "net_profit_growth_percent": 0.5406623113313858,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Nahdi",
      "company_ar": "النهدي",
      "ticker": "4164",
      "sector": "pharmacies",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 8713.7,
      "net_profit_attributable_to_owners": 892.6,
      "net_margin_percent": 10.243639326577687,
      "revenue_growth_percent": 1.13158933172397,
      "net_profit_original_superseded": null,
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_urls": "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1 | https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en | https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1 | https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
    },
    {
      "net_profit_growth_percent": -8.052879229218012,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Nahdi",
      "company_ar": "النهدي",
      "ticker": "4164",
      "sector": "pharmacies",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 9446.42,
      "net_profit_attributable_to_owners": 820.72,
      "net_margin_percent": 8.68815911212925,
      "revenue_growth_percent": 8.408827478568215,
      "net_profit_original_superseded": null,
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_urls": "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1 | https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en | https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1 | https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
    },
    {
      "net_profit_growth_percent": 1.2208792279949199,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Nahdi",
      "company_ar": "النهدي",
      "ticker": "4164",
      "sector": "pharmacies",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 10213.24,
      "net_profit_attributable_to_owners": 830.74,
      "net_margin_percent": 8.133951615745836,
      "revenue_growth_percent": 8.117572583052635,
      "net_profit_original_superseded": null,
      "notes": "Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained Consolidated reported net profit after zakat; source precision retained",
      "source_urls": "https://www.argaam.com/sa-en/switch-view?mobile=false&returnUrl=https%3A%2F%2Fwww.argaam.com%2Fsa-en%2Ffinancial-reports%2Fcompany-report%2F12760%2F2021%2F1 | https://investors.nahdi.sa/wp-content/uploads/2023/03/Annual-Financials-Announcement-FY-2022-EN-1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=78760&cs=4164&locale=en | https://betapp.argaamcharts.com/en/financial-reports/company-report/12760/2024/1 | https://www.argaam.com/en/financial-reports/company-report/12760/2025/1"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Al-Dawaa",
      "company_ar": "الدواء",
      "ticker": "4163",
      "sector": "pharmacies",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 5034.382,
      "net_profit_attributable_to_owners": 239.145,
      "net_margin_percent": 4.750235480740239,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_urls": "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf | https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
    },
    {
      "net_profit_growth_percent": 27.72543854147065,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Al-Dawaa",
      "company_ar": "الدواء",
      "ticker": "4163",
      "sector": "pharmacies",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 5372.243,
      "net_profit_attributable_to_owners": 305.449,
      "net_margin_percent": 5.685688454524488,
      "revenue_growth_percent": 6.711071984605077,
      "net_profit_original_superseded": null,
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_urls": "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf | https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
    },
    {
      "net_profit_growth_percent": -0.8043896035017317,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Al-Dawaa",
      "company_ar": "الدواء",
      "ticker": "4163",
      "sector": "pharmacies",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 5741.364,
      "net_profit_attributable_to_owners": 302.992,
      "net_margin_percent": 5.2773522110773685,
      "revenue_growth_percent": 6.870891729953366,
      "net_profit_original_superseded": null,
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_urls": "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf | https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
    },
    {
      "net_profit_growth_percent": 15.979299783492639,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Al-Dawaa",
      "company_ar": "الدواء",
      "ticker": "4163",
      "sector": "pharmacies",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 6454.354,
      "net_profit_attributable_to_owners": 351.408,
      "net_margin_percent": 5.444510790700355,
      "revenue_growth_percent": 12.418477560384611,
      "net_profit_original_superseded": null,
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_urls": "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf | https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
    },
    {
      "net_profit_growth_percent": -8.438054910531356,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Al-Dawaa",
      "company_ar": "الدواء",
      "ticker": "4163",
      "sector": "pharmacies",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 6736.196,
      "net_profit_attributable_to_owners": 321.756,
      "net_margin_percent": 4.776523723478354,
      "revenue_growth_percent": 4.3666957219886005,
      "net_profit_original_superseded": null,
      "notes": "2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions 2025 company annual-report five-year table; SAR thousands converted to millions",
      "source_urls": "https://argaamplus.s3.amazonaws.com/ac06d8ea-631d-4966-a049-997bd33bd4d1.pdf | https://financialfilings.com/filings/aldawaa-medical-services-co/annual-report/2026/64531520/"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "SPIMACO",
      "company_ar": "سبيماكو الدوائية",
      "ticker": "2070",
      "sector": "pharma",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1459.78,
      "net_profit_attributable_to_owners": 26.45,
      "net_margin_percent": 1.811916864185014,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71 | https://www.argaam.com/en/financial-reports/company-report/75/2024/1 | https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true | https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf | https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
    },
    {
      "net_profit_growth_percent": -724.3478260869565,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "SPIMACO",
      "company_ar": "سبيماكو الدوائية",
      "ticker": "2070",
      "sector": "pharma",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1421.81,
      "net_profit_attributable_to_owners": -165.14,
      "net_margin_percent": -11.614772719280353,
      "revenue_growth_percent": -2.601076874597541,
      "net_profit_original_superseded": null,
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71 | https://www.argaam.com/en/financial-reports/company-report/75/2024/1 | https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true | https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf | https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "SPIMACO",
      "company_ar": "سبيماكو الدوائية",
      "ticker": "2070",
      "sector": "pharma",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1655.44,
      "net_profit_attributable_to_owners": -50.73,
      "net_margin_percent": -3.0644420818634317,
      "revenue_growth_percent": 16.431872050414633,
      "net_profit_original_superseded": null,
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71 | https://www.argaam.com/en/financial-reports/company-report/75/2024/1 | https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true | https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf | https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "SPIMACO",
      "company_ar": "سبيماكو الدوائية",
      "ticker": "2070",
      "sector": "pharma",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1682,
      "net_profit_attributable_to_owners": 24.54,
      "net_margin_percent": 1.4589774078478002,
      "revenue_growth_percent": 1.6044072874885185,
      "net_profit_original_superseded": null,
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71 | https://www.argaam.com/en/financial-reports/company-report/75/2024/1 | https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true | https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf | https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
    },
    {
      "net_profit_growth_percent": 651.2632436837816,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "SPIMACO",
      "company_ar": "سبيماكو الدوائية",
      "ticker": "2070",
      "sector": "pharma",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1706.71,
      "net_profit_attributable_to_owners": 184.36,
      "net_margin_percent": 10.802069478704643,
      "revenue_growth_percent": 1.4690844233056,
      "net_profit_original_superseded": null,
      "notes": "\"\" Manufacturing-led consolidated group includes hospital and service subsidiaries; not a pure manufacturing segment.",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/75/2024/71 | https://www.argaam.com/en/financial-reports/company-report/75/2024/1 | https://www.argaam.com/en/financial-reports/company-report/75/2025/1?preview=true | https://ir.spimaco.com.sa/media/iijbkrox/spimaco_annual-report_2025_en.pdf | https://ir.spimaco.com.sa/media/m30lmsdh/spimaco_fs_fy24_en.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Jamjoom Pharma",
      "company_ar": "جمجوم فارما",
      "ticker": "4015",
      "sector": "pharma",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 735.68,
      "net_profit_attributable_to_owners": 170.7,
      "net_margin_percent": 23.20302305350152,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71 | https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1 | https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
    },
    {
      "net_profit_growth_percent": 0.3573520796719576,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Jamjoom Pharma",
      "company_ar": "جمجوم فارما",
      "ticker": "4015",
      "sector": "pharma",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 916.67,
      "net_profit_attributable_to_owners": 171.31,
      "net_margin_percent": 18.688295678924803,
      "revenue_growth_percent": 24.601729012614193,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71 | https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1 | https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
    },
    {
      "net_profit_growth_percent": 70.68472360049032,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Jamjoom Pharma",
      "company_ar": "جمجوم فارما",
      "ticker": "4015",
      "sector": "pharma",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1100.82,
      "net_profit_attributable_to_owners": 292.4,
      "net_margin_percent": 26.56201740520703,
      "revenue_growth_percent": 20.089017858116875,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71 | https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1 | https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
    },
    {
      "net_profit_growth_percent": 21.92886456908345,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Jamjoom Pharma",
      "company_ar": "جمجوم فارما",
      "ticker": "4015",
      "sector": "pharma",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1318.48,
      "net_profit_attributable_to_owners": 356.52,
      "net_margin_percent": 27.040228141496264,
      "revenue_growth_percent": 19.77253320252177,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71 | https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1 | https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
    },
    {
      "net_profit_growth_percent": 30.090878492090223,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Jamjoom Pharma",
      "company_ar": "جمجوم فارما",
      "ticker": "4015",
      "sector": "pharma",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 1500.63,
      "net_profit_attributable_to_owners": 463.8,
      "net_margin_percent": 30.90701905199816,
      "revenue_growth_percent": 13.815150779685714,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://www.argaam.com/sa-en/financial-reports/company-report/15187/2024/71 | https://www.argaam.com/sa-en/financial-reports/company-report/15187/2025/1 | https://investors.jamjoompharma.com/media/xoslv5aq/jp-earnings-release-fy-2025-en.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Avalon Pharma",
      "company_ar": "أفالون فارما",
      "ticker": "4016",
      "sector": "pharma",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 287.222,
      "net_profit_attributable_to_owners": 66.283,
      "net_margin_percent": 23.077271239668274,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf | https://www.argaam.com/en/financial-reports/company-report/16437/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1 | https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
    },
    {
      "net_profit_growth_percent": -10.305809936182742,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Avalon Pharma",
      "company_ar": "أفالون فارما",
      "ticker": "4016",
      "sector": "pharma",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 302.662,
      "net_profit_attributable_to_owners": 59.452,
      "net_margin_percent": 19.64303414369825,
      "revenue_growth_percent": 5.375632785789386,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf | https://www.argaam.com/en/financial-reports/company-report/16437/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1 | https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
    },
    {
      "net_profit_growth_percent": 10.727982237771648,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Avalon Pharma",
      "company_ar": "أفالون فارما",
      "ticker": "4016",
      "sector": "pharma",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 338.44,
      "net_profit_attributable_to_owners": 65.83,
      "net_margin_percent": 19.4510105188512,
      "revenue_growth_percent": 11.821107373902251,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf | https://www.argaam.com/en/financial-reports/company-report/16437/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1 | https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
    },
    {
      "net_profit_growth_percent": 21.297280874981016,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Avalon Pharma",
      "company_ar": "أفالون فارما",
      "ticker": "4016",
      "sector": "pharma",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 394,
      "net_profit_attributable_to_owners": 79.85,
      "net_margin_percent": 20.26649746192893,
      "revenue_growth_percent": 16.416499231769286,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf | https://www.argaam.com/en/financial-reports/company-report/16437/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1 | https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
    },
    {
      "net_profit_growth_percent": 21.490294301815926,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Avalon Pharma",
      "company_ar": "أفالون فارما",
      "ticker": "4016",
      "sector": "pharma",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 460.49,
      "net_profit_attributable_to_owners": 97.01,
      "net_margin_percent": 21.066689830398055,
      "revenue_growth_percent": 16.875634517766503,
      "net_profit_original_superseded": null,
      "notes": "\"\"",
      "source_urls": "https://cma.gov.sa/en/Market/Prospectuses/Documents/avalon_pharma_en.pdf | https://www.argaam.com/en/financial-reports/company-report/16437/2024/1 | https://www.argaam.com/sa-en/financial-reports/company-report/16437/2025/1 | https://www.saudiexchange.sa/Resources/fsPdf/5507_0_2026-03-12_01-15-25_En.pdf"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "missing",
      "company": "Smile Care (Basma Adeem Medical)",
      "company_ar": "سمايل كير",
      "ticker": "9626",
      "sector": "clinics",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": null,
      "net_profit_attributable_to_owners": null,
      "net_margin_percent": null,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Smile Care (Basma Adeem Medical)",
      "company_ar": "سمايل كير",
      "ticker": "9626",
      "sector": "clinics",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 21.922123,
      "net_profit_attributable_to_owners": 3.783343,
      "net_margin_percent": 17.258104974595753,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
    },
    {
      "net_profit_growth_percent": 28.70572401180651,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Smile Care (Basma Adeem Medical)",
      "company_ar": "سمايل كير",
      "ticker": "9626",
      "sector": "clinics",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 26.524465,
      "net_profit_attributable_to_owners": 4.869379,
      "net_margin_percent": 18.35806678852901,
      "revenue_growth_percent": 20.994052446471546,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
    },
    {
      "net_profit_growth_percent": 29.397506334996713,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Smile Care (Basma Adeem Medical)",
      "company_ar": "سمايل كير",
      "ticker": "9626",
      "sector": "clinics",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 33.918786,
      "net_profit_attributable_to_owners": 6.300855,
      "net_margin_percent": 18.576298691822288,
      "revenue_growth_percent": 27.877361522654653,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
    },
    {
      "net_profit_growth_percent": 15.930234864950865,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Smile Care (Basma Adeem Medical)",
      "company_ar": "سمايل كير",
      "ticker": "9626",
      "sector": "clinics",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 45.4569,
      "net_profit_attributable_to_owners": 7.304596,
      "net_margin_percent": 16.069278811357574,
      "revenue_growth_percent": 34.01688374106313,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/IPO/PDF/IPO_ENG_2025-02-02_12-00-20_1.pdf | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=1&anId=93675&cs=9626&locale=en"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Al Mudaawat Specialized Medical",
      "company_ar": "المداواة",
      "ticker": "9594",
      "sector": "clinics",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 40.837386,
      "net_profit_attributable_to_owners": -2.2,
      "net_margin_percent": -5.387220425910709,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf | https://www.argaam.com/ar/article/articledetail/id/1717264 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar | https://www.argaam.com/ar/article/articledetail/id/1700773"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Al Mudaawat Specialized Medical",
      "company_ar": "المداواة",
      "ticker": "9594",
      "sector": "clinics",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 58.56579,
      "net_profit_attributable_to_owners": 10.313266,
      "net_margin_percent": 17.60971037870402,
      "revenue_growth_percent": 43.4121909761805,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf | https://www.argaam.com/ar/article/articledetail/id/1717264 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar | https://www.argaam.com/ar/article/articledetail/id/1700773"
    },
    {
      "net_profit_growth_percent": 80.2791666577784,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Al Mudaawat Specialized Medical",
      "company_ar": "المداواة",
      "ticker": "9594",
      "sector": "clinics",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 74.308118,
      "net_profit_attributable_to_owners": 18.59267,
      "net_margin_percent": 25.021048171345157,
      "revenue_growth_percent": 26.879733031860397,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf | https://www.argaam.com/ar/article/articledetail/id/1717264 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar | https://www.argaam.com/ar/article/articledetail/id/1700773"
    },
    {
      "net_profit_growth_percent": -67.33546607345798,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Al Mudaawat Specialized Medical",
      "company_ar": "المداواة",
      "ticker": "9594",
      "sector": "clinics",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 75.487734,
      "net_profit_attributable_to_owners": 6.073209,
      "net_margin_percent": 8.045292497453957,
      "revenue_growth_percent": 1.5874658539999809,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf | https://www.argaam.com/ar/article/articledetail/id/1717264 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar | https://www.argaam.com/ar/article/articledetail/id/1700773"
    },
    {
      "net_profit_growth_percent": 212.44161035788488,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Al Mudaawat Specialized Medical",
      "company_ar": "المداواة",
      "ticker": "9594",
      "sector": "clinics",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 121.820505,
      "net_profit_attributable_to_owners": 18.975232,
      "net_margin_percent": 15.57638592944595,
      "revenue_growth_percent": 61.37788027919873,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/Resources/fsPdf/19436_5486_2024-05-19_15-30-35_ar.pdf | https://www.argaam.com/ar/article/articledetail/id/1717264 | https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details?anCat=1&anId=93294&locale=ar | https://www.argaam.com/ar/article/articledetail/id/1700773"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Future Care Trading",
      "company_ar": "الرعاية المستقبلية",
      "ticker": "9544",
      "sector": "clinics",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 72.028,
      "net_profit_attributable_to_owners": 36.701,
      "net_margin_percent": 50.95379574609874,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en | https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
    },
    {
      "net_profit_growth_percent": -86.03035339636523,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Future Care Trading",
      "company_ar": "الرعاية المستقبلية",
      "ticker": "9544",
      "sector": "clinics",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 34.125,
      "net_profit_attributable_to_owners": 5.127,
      "net_margin_percent": 15.024175824175822,
      "revenue_growth_percent": -52.62259121452768,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en | https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
    },
    {
      "net_profit_growth_percent": 166.4911254144724,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Future Care Trading",
      "company_ar": "الرعاية المستقبلية",
      "ticker": "9544",
      "sector": "clinics",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 50.98,
      "net_profit_attributable_to_owners": 13.663,
      "net_margin_percent": 26.80070615927815,
      "revenue_growth_percent": 49.39194139194139,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en | https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
    },
    {
      "net_profit_growth_percent": -27.88553026421723,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Future Care Trading",
      "company_ar": "الرعاية المستقبلية",
      "ticker": "9544",
      "sector": "clinics",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 53.644,
      "net_profit_attributable_to_owners": 9.853,
      "net_margin_percent": 18.367384982477073,
      "revenue_growth_percent": 5.225578658297381,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en | https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
    },
    {
      "net_profit_growth_percent": 59.88023952095809,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Future Care Trading",
      "company_ar": "الرعاية المستقبلية",
      "ticker": "9544",
      "sector": "clinics",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 76.062,
      "net_profit_attributable_to_owners": 15.753,
      "net_margin_percent": 20.71073597854382,
      "revenue_growth_percent": 41.790321377973314,
      "net_profit_original_superseded": null,
      "notes": "Mixed outpatient/home-care/regional hospital models; not equivalent peers. Mudaawat2021 net loss is approximately SAR2.2m, rounded to nearest SAR0.1m; applicable only to Mudaawat. Smile2021 unavailable; applicable only to Smile.",
      "source_urls": "https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anCat=17&anId=72725&cs=9544&locale=en | https://www.saudiexchange.sa/wps/portal/saudiexchange/hidden/company-profile-main/%21ut/p/z1/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTR3NDIw8LAz83d2MXA0C3SydAl1c3Q0NvE30I4EKzBEKDMKcTQzMDPxN3H19LAzdTU31w8syU8v1wwkpK8hOMgUA-oskdg%21%21/?companySymbol=9544&csrt=15813097196958540468"
    },
    {
      "net_profit_growth_percent": null,
      "period_end": "2021-12-31",
      "completeness": "both",
      "company": "Scientific and Medical Equipment House",
      "company_ar": "دار المعدات",
      "ticker": "4014",
      "sector": "suppliers",
      "year": 2021,
      "currency": "SAR",
      "unit": "million",
      "revenue": 699.453,
      "net_profit_attributable_to_owners": 77.524,
      "net_margin_percent": 11.083518120588517,
      "revenue_growth_percent": null,
      "net_profit_original_superseded": null,
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_urls": "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf | https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf | https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
    },
    {
      "net_profit_growth_percent": -77.33992054073578,
      "period_end": "2022-12-31",
      "completeness": "both",
      "company": "Scientific and Medical Equipment House",
      "company_ar": "دار المعدات",
      "ticker": "4014",
      "sector": "suppliers",
      "year": 2022,
      "currency": "SAR",
      "unit": "million",
      "revenue": 713.821,
      "net_profit_attributable_to_owners": 17.567,
      "net_margin_percent": 2.460981114312972,
      "revenue_growth_percent": 2.054176620873749,
      "net_profit_original_superseded": null,
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_urls": "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf | https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf | https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
    },
    {
      "net_profit_growth_percent": 128.03293106392667,
      "period_end": "2023-12-31",
      "completeness": "both",
      "company": "Scientific and Medical Equipment House",
      "company_ar": "دار المعدات",
      "ticker": "4014",
      "sector": "suppliers",
      "year": 2023,
      "currency": "SAR",
      "unit": "million",
      "revenue": 776.666162,
      "net_profit_attributable_to_owners": 40.058545,
      "net_margin_percent": 5.157755926541834,
      "revenue_growth_percent": 8.804050595317303,
      "net_profit_original_superseded": null,
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_urls": "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf | https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf | https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
    },
    {
      "net_profit_growth_percent": -34.67538823489471,
      "period_end": "2024-12-31",
      "completeness": "both",
      "company": "Scientific and Medical Equipment House",
      "company_ar": "دار المعدات",
      "ticker": "4014",
      "sector": "suppliers",
      "year": 2024,
      "currency": "SAR",
      "unit": "million",
      "revenue": 877.232651,
      "net_profit_attributable_to_owners": 26.168089,
      "net_margin_percent": 2.9830272471242063,
      "revenue_growth_percent": 12.948483392276344,
      "net_profit_original_superseded": null,
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_urls": "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf | https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf | https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
    },
    {
      "net_profit_growth_percent": 8.678169047804762,
      "period_end": "2025-12-31",
      "completeness": "both",
      "company": "Scientific and Medical Equipment House",
      "company_ar": "دار المعدات",
      "ticker": "4014",
      "sector": "suppliers",
      "year": 2025,
      "currency": "SAR",
      "unit": "million",
      "revenue": 876.707,
      "net_profit_attributable_to_owners": 28.439,
      "net_margin_percent": 3.2438431539841703,
      "revenue_growth_percent": -0.059921504221349675,
      "net_profit_original_superseded": null,
      "notes": "Revenue2023 onward continuing operations, with2023 comparator restated in2024 financial statements.2021–22 revenue original consolidated basis; do not treat entire revenue CAGR as strict like-for-like. Owner net profits include discontinued operations for all years.",
      "source_urls": "https://argaamplus.s3.amazonaws.com/8e97159c-9a56-41c4-a735-9eb078aa6700.pdf | https://argaamplus.s3.amazonaws.com/548325f9-0065-460c-ab68-a45de8ac6cff.pdf | https://www.smeh.com.sa/en/post/195/scientific-medical-equipment-house-co-announces-it"
    }
  ]
}